货币 / KYMR
KYMR: Kymera Therapeutics Inc
44.48
USD
0.09
(0.20%)
今日KYMR汇率已更改-0.20%。当日,交易品种以低点43.87和高点45.15进行交易。
关注Kymera Therapeutics Inc动态。实时报价将帮助您快速应对市场变化。通过在不同的时间周期之间切换,您可以按分钟、小时、天、周和月监控汇率趋势和动态。使用这些信息来预测市场变化并做出明智的交易决策。
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
KYMR新闻
- Benzinga Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' - iShares U.S. Financial ETF (ARCA:IYF), Gilead Sciences (NASDAQ:GILD)
- Investing Kymera Therapeutics stock price target lowered to $65 at Brookline Capital
- Investing Morgan Stanley initiates Kymera Therapeutics stock with Overweight rating
- Investing Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion
- Investing Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets
- Investing Kymera Therapeutics (KYMR) director group buys $13.9 million in stock
- Investing Monday’s Insider Activity: Top Buys and Sells in US Stocks
- Investing Kymera Therapeutics: Baker Bros acquire $28.8m in shares
- Investing Kymera price target raised to $54 from $51 at BofA on pipeline updates
- Investing Kymera’s partnerships with Sanofi and Gilead drive value
- Investing Kymera Therapeutics Announces Pricing of $250 Million Public Offering
- Benzinga Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Apple (NASDAQ:AAPL), Alnylam Pharmaceuticals (NASDAQ:ALNY)
- Investing Kymera stock price target raised to $60 from $54 at H.C. Wainwright
- Investing Kymera Therapeutics price target lowered to $70 at Brookline Capital
- Investing Kymera Therapeutics launches $250 million public stock offering
- Investing Kymera Therapeutics stock falls after announcing $250 million offering
- Investing Kymera stock falls as Jefferies lowers price target on program shifts
- Seeking Alpha Kymera Shrugs Off Sanofi Bust With Gilead Deal - But There Are Caveats (NASDAQ:KYMR)
- Investing Kymera stock falls as Sanofi drops IRAK4 degrader for next-gen candidate
- Benzinga Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies - Gilead Sciences (NASDAQ:GILD), Sanofi (NASDAQ:SNY)
- Investing Sanofi to advance Kymera’s oral IRAK4 degrader KT-485 to clinical testing
- Seeking Alpha Tracking Baker Brothers Portfolio – Q1 2025 Update
- Investing Kymera at Goldman Sachs Conference: Pioneering Oral Protein Degraders
- Benzinga Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? - Applied Digital (NASDAQ:APLD), Riot Platforms (NASDAQ:RIOT)
日范围
43.87
45.15
年范围
19.44
53.27
- 前一天收盘价
- 45.21
- 开盘价
- 44.57
- 卖价
- 44.48
- 买价
- 44.78
- 最低价
- 43.87
- 最高价
- 45.15
- 交易量
- 1.357 K
- 日变化
- -0.20%
- 月变化
- -1.20%
- 6个月变化
- 16.44%
- 年变化
- -4.51%
12 七月, 星期六